~~<i id='22D3B58E4A'><strike id='22D3B58E4A'><tt id='22D3B58E4A'><pre id='22D3B58E4A'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-09-30 06:48:29 Page View：761

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approves updated Covid vaccines
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Telehealth for opioid use disorder is lifesaving

JoeRaedle/GettyImagesThestatisticsaredismal,thoughtheybearrepeating:81%ofoverdosedeathsintheU.S.in20

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Will General Catalyst be the first of many hospital takeovers?

AdobeGeneralCatalyst’splantotakeoverahospitalinthecomingmonthscouldbethefirstofmanysuchdeals,drivenb